Germline Genetic Variation Modulates Tumor Progression and Metastasis in a Mouse Model of Neuroendocrine Prostate Carcinoma

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Patel, Shashank J ^a   Molinolo, Alfredo A ^b   Gutkind, Silvio ^b   Crawford, Nigel P S ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3BETA; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DISTANT METASTASIS; GENETIC VARIABILITY; GERMLINE VARIATION; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MOUSE; NEUROENDOCRINE PROSTATE CARCINOMA; NONHUMAN; PROSTATE CARCINOMA; QUANTITATIVE ANALYSIS; STRAIN DIFFERENCE; TUMOR PROMOTION; TUMOR VOLUME; WILD TYPE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CARCINOMA, NEUROENDOCRINE; CELL TRANSFORMATION, NEOPLASTIC; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITHELIUM; FEMALE; GENETIC VARIATION; GENOTYPE; GERM CELLS; HUMANS; MALE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; NEOPLASM METASTASIS; PHENOTYPE; PROSTATE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 84876436625     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061848     Document Type: Article

References (41)

1. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK, (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8: 541-552.
2. Sun Y, Niu J, Huang J, (2009) Neuroendocrine differentiation in prostate cancer. Am J Transl Res 1: 148-162.
3. Cindolo L, Cantile M, Vacherot F, Terry S, de la Taille A, (2007) Neuroendocrine differentiation in prostate cancer: from lab to bedside. Urol Int 79: 287-296.
4. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, et al. (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64: 2270-2305.
5. Fixemer T, Remberger K, Bonkhoff H, (2002) Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 53: 118-123.
6. Grobholz R, Griebe M, Sauer CG, Michel MS, Trojan L, et al. (2005) Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol 36: 562-570.
7. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, et al. (2010) Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18: 23-38.
8. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, et al. (2011) Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discov 1: 487-495.
9. Hunter KW, Broman KW, Voyer TL, Lukes L, Cozma D, et al. (2001) Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res 61: 8866-8872.
10. Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, et al. (2005) Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 37: 1055-1062.
11. Crawford NP, Qian X, Ziogas A, Papageorge AG, Boersma BJ, et al. (2007) Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genet 3: e214.
12. Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, et al. (1998) Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 77: 640-644.
13. Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, et al. (2006) Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 8: R16.
14. Crawford NP, Alsarraj J, Lukes L, Walker RC, (2008) Officewala JS, et al (2008) Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci U S A 105: 6380-6385.
15. Crawford NP, Walker RC, Lukes L, (2008) Officewala JS, Williams RW, et al (2008) The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survival. Clin Exp Metastasis 25: 357-369.
16. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, et al. (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res 56: 4096-4102.
17. Wang F, (2011) Modeling human prostate cancer in genetically engineered mice. Prog Mol Biol Transl Sci 100: 1-49.
18. Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, et al. (2008) Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. Prostate 68: 1517-1530.
19. Roberts A, Pardo-Manuel de Villena F, Wang W, McMillan L, Threadgill DW, (2007) The polymorphism architecture of mouse genetic resources elucidated using genome-wide resequencing data: implications for QTL discovery and systems genetics. Mamm Genome 18: 473-481.
20. Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, et al. (2004) The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet 36: 1133-1137.
21. Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, et al. (2000) Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). Biotechniques 29: 52, 54.
22. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED (2001) The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol Chapter 20: Unit 20 25.
23. Chiaverotti T, Couto SS, Donjacour A, Mao J-H, Nagase H, et al. (2008) Dissociation of Epithelial and Neuroendocrine Carcinoma Lineages in the Transgenic Adenocarcinoma of Mouse Prostate Model of Prostate Cancer. The American Journal of Pathology 172: 236-246.
24. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM, (1999) Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 2: 70-75.
25. Tani Y, Suttie A, Flake GP, Nyska A, Maronpot RR, (2005) Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model. Vet Pathol 42: 306-314.
26. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, et al. (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55: 219-237.
27. Sella A, Konichezky M, Flex D, Sulkes A, Baniel J, (2000) Low PSA metastatic androgen- independent prostate cancer. Eur Urol 38: 250-254.
28. Vashchenko N, Abrahamsson PA, (2005) Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 47: 147-155.
29. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, et al. (2003) Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 55: 168-179.
30. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, et al. (2005) Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 12: 109-117.
31. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED (2001) The TRAMP Mouse as a Model for Prostate Cancer. Current Protocols in Immunology. Hoboken, NJ: John Wiley & Sons, Inc.
32. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, et al. (1997) Androgen-independent Prostate Cancer Progression in the TRAMP Model. Cancer Research 57: 4687-4691.
33. Balmain A, Gray J, Ponder B, (2003) The genetics and genomics of cancer. Nat Genet 33Suppl: 238-244.
34. Talbot CJ, Nicod A, Cherny SS, Fulker DW, Collins AC, et al. (1999) High-resolution mapping of quantitative trait loci in outbred mice. Nat Genet 21: 305-308.
35. Hunter KW, Crawford NP, (2008) The future of mouse QTL mapping to diagnose disease in mice in the age of whole-genome association studies. Annu Rev Genet 42: 131-141.
36. Navarro SJ, Trinh T, Lucas CA, Ross AJ, Waymire KG, et al. (2012) The C57BL/6J Mouse Strain Background Modifies the Effect of a Mutation in Bcl2l2. G3 (Bethesda) 2: 99-102.
37. Hunter KW, (2012) Mouse models of cancer: does the strain matter? Nat Rev Cancer 12: 144-149.
38. Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, et al. (2002) Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol 168: 1204-1211.
39. Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, et al. (2006) Expression and role of Foxa proteins in prostate cancer. Prostate 66: 1013-1028.
40. Wang Q, Li W, Zhang Y, Yuan X, Xu K, et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245-256.
41. Gerhardt J, Montani M, Wild P, Beer M, Huber F, et al. (2012) FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol 180: 848-861.